# Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates

> **NCT05404919** · PHASE2 · WITHDRAWN · sponsor: **University of Pennsylvania**

## Conditions studied

- Lung Transplant
- Hepatitis B

## Interventions

- **DRUG:** Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide

## Key facts

- **NCT ID:** NCT05404919
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-06
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Insufficient enrollment; departure of primary investigator from institution
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05404919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05404919, "Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05404919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*